A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis

被引:165
|
作者
Nishiyama, O. [1 ,3 ]
Taniguchi, H. [1 ]
Kondoh, Y. [1 ]
Kimura, T. [1 ]
Kato, K. [1 ]
Kataoka, K. [1 ]
Ogawa, T. [2 ]
Watanabe, F. [2 ]
Arizono, S. [2 ]
机构
[1] Tosei Gen Hosp, Dept Resp Med & Allergy, Aichi 4898642, Japan
[2] Tosei Gen Hosp, Dept Rehabil, Aichi 4898642, Japan
[3] Kinki Univ, Sch Med, Dept Resp Med & Allergol, Osaka 589, Japan
关键词
Dyspnoea; idiopathic pulmonary fibrosis; mortality; EXERCISE CAPACITY; SURVIVAL; OBSTRUCTION; FEATURES; PREDICTS; LUNG;
D O I
10.1183/09031936.00152609
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The prognosis in idiopathic pulmonary fibrosis (IPF) is poor. No therapy has been shown to prolong survival. The objective of this study was to examine the prognostic significance of dyspnoea in daily living at baseline in IPF using a simple assessment tool. 93 consecutive patients with IPF, who had undergone evaluation at diagnosis, were included. The level of dyspnoea was assessed using the modified Medical Research Council (MRC) scale. The relationship between data at baseline and survival was examined. A univariate Cox proportional-hazard model showed that forced vital capacity % predicted (hazard ratio (HR) 0.965, 95% CI 0.948-0.982; p<0.0001), diffusing capacity of the lung for carbon monoxide % predicted (HR 0.978, 95% CI 0.963-0.993; p=0.0041), baseline arterial oxygen tension (HR 0.963, 95% CI 0.938-0.989; p=0.0060) and modified MRC score (HR 2.402, 95% CI 1.495-3.858; p=0.0003) were significantly predictive of survival. All variables of the 6-min walk test, including walk distance (HR 0.995, 95% CI 0.992-0.998; p=0.0020), the lowest arterial oxygen saturation measured by pulse oximetry (Sp,O-2) (HR 0.944, 95% CI 0.918-0.972; p<0.0001) and the Borg scale (HR 1.285, 95% CI 1.091-1.514; p=0.0027), were also significant. With stepwise, multivariate Cox proportional analysis, the modified MRC score (HR 2.181, 95% CI 1.333-3.568; p=0.0019) and the lowest Sp,O-2 during the 6-min walk test (HR 0.952, 95% CI 0.924-0.981; p=0.0014) were the most significant. Dyspnoea in daily living, assessed with the modified MRC scale at baseline, provides additional prognostic information for patients with IPF.
引用
收藏
页码:1067 / 1072
页数:6
相关论文
共 50 条
  • [41] Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis
    Miki, K
    Maekura, R
    Hiraga, T
    Okuda, Y
    Okamoto, T
    Hirotani, A
    Ogura, T
    [J]. RESPIRATORY MEDICINE, 2003, 97 (05) : 482 - 490
  • [42] Prognostic Value Of Peripheral Blood Biomarkers In Idiopathic Pulmonary Fibrosis
    Song, J. W.
    Kim, M. Y.
    Jang, S. J.
    Colby, T. V.
    Kim, D. S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [43] Blood lipid profiles as a prognostic biomarker in idiopathic pulmonary fibrosis
    Oh, Ju Hyun
    Chae, Ganghee
    Song, Jin Woo
    [J]. RESPIRATORY RESEARCH, 2024, 25 (01)
  • [44] Effects Of Emphysema On Physiologic And Prognostic Characteristics In Idiopathic Pulmonary Fibrosis
    Kim, T.
    Lee, S.
    Lee, S.
    Kim, N.
    Seo, J.
    Song, J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [45] VISTA is a novel diagnostic and prognostic biomarker in idiopathic pulmonary fibrosis
    Yoon, Hee-Young
    Chae, Ganghee
    Lee, Sang Eun
    Moon, Su-Jin
    Song, Jin Woo
    [J]. RESPIROLOGY, 2023, 28 : 365 - 366
  • [46] IDENTIFICATION OF CLINICAL PROGNOSTIC PARAMETERS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Rogers, K.
    Hadinnapola, C.
    Sylvester, K.
    Toshner, M.
    Parfrey, H.
    [J]. THORAX, 2016, 71 : A14 - A14
  • [47] Prognostic modeling in idiopathic pulmonary fibrosis using deep learning
    Anegondi, Neha
    Zou, Yixuan
    Hou, Xuefeng
    Negahdar, Mohammadreza
    Cheung, Dorothy
    Belloni, Paula
    De Crespigny, Alex
    Coimbra, Alexandre Fernandez
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [48] The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis
    Fell, Charlene D.
    Liu, Lyrica Xiaohong
    Motilka, Caroline
    Kazerooni, Ella A.
    Gross, Barry H.
    Travis, William D.
    Colby, Thomas V.
    Murray, Susan
    Toews, Galen B.
    Martinez, Fernando J.
    Flaherty, Kevin R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (05) : 402 - 407
  • [49] Evaluating the Prognostic Blood Biomarkers in Patients with idiopathic pulmonary Fibrosis
    Lichert, Frank
    [J]. PNEUMOLOGIE, 2022, 76 (10):
  • [50] Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
    Raghu, G.
    King, T. E., Jr.
    Behr, J.
    Brown, K. K.
    du Bois, R. M.
    Leconte, I.
    Roux, S.
    Swigris, J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (01) : 118 - 123